Michael G. Erickson's most recent trade in Idexx Laboratories, Inc. was a trade of 6,320 Non-Qualified Stock Option (right-to-buy) done . Disclosure was reported to the exchange on Feb. 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 6,320 | 6,320 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 734 | 734 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 734 | 734 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 301 | 903 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 301 | 21,393 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 217 | 217 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 444.53 per share. | 13 Feb 2025 | 177 | 21,216 (0%) | 0% | 444.5 | 78,682 | Common Stock |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 94 | 21,092 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 94 | 188 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 93 | 92 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 93 | 20,998 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 69 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 69 | 20,905 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.85 per share. | 11 Feb 2025 | 1,544 | 20,836 (0%) | 0% | 67.8 | 104,760 | Common Stock |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2025 | 1,544 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Michael Erickson G. | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 5,407 | 5,407 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Michael Erickson G. | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 1,204 | 1,204 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Erickson Michael G. | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 178 | 178 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Michael Erickson G. | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 560.56 per share. | 14 Feb 2024 | 144 | 10,657 (0%) | 0% | 560.6 | 80,721 | Common Stock |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 108 | 10,447 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Erickson Michael G. | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 108 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 97 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Michael Erickson G. | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 97 | 10,544 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | G. Michael Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 95 | 10,801 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Erickson G. Michael | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 95 | 282 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Erickson Michael G. | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 93 | 185 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Michael G. Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 93 | 10,706 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Erickson Michael G. | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 69 | 69 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | G. Michael Erickson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 69 | 10,613 (0%) | 0% | 0 | Common Stock |